Thermodynamic Properties of ELP-Labelled Doxorubicin, a Drug Delivery System  by Zai-Rose, Valeria
54a Sunday, February 8, 2015268-Pos Board B48
Probing the Dependence of pH on Sugar Binding and Protein Structure in
a Polysaccharide Lyase
Sook Wong, Jeffery B. Klauda.
Chemical and Biomolecular Engineering, University of Maryland, College
Park, MD, USA.
Polysaccharide lyases (PLs) are enzymes that our commonly used by microor-
ganisms to degrade polyuronides. These enzymes are produced by bacteria to
aid in reducing the high molecular weight of the host’s extracellular matrix
to enhance its virulence. PLs can also be used to degrade polysaccharides as
a source of carbon for the pathogen. Our focus is on the alginate lyase of Sten-
otrophomonas maltophilia (Smlt1473), which has been shown recently to be
active against alginate, hyaluronic acid (HA) and poly-D-glucuronic acid at
varying pH values (J. Biol. Chem. 289: 312 (2014)). The active site appears
to have regions specific to binding these three sugars and an active catalytic
site. Our objective is to understand how pH influences binding of a HA and
if this involves structural changes in the protein. Docking of HA to a
homology-based structure of Smlt1473 (based on the crystal structure of algi-
nate lyase A1-III) was used to provide initial starting conformations for our
molecular dynamics (MD) simulations. ProPKa was used to determine the ioni-
zation state of residues at our three simulated pHs (5, 7 and 9). MD simulations
at neutral pH confirm the binding residues seen in experiment. However, at the
acidic and basic condtions, the homology-based model of the binding pocket
opens. At ph¼5, there is an increase in the exposure of HA-specific residues
in the vicinity of W171 suggesting this exposure is the cause for Smlt1473
increased activity (J. Biol. Chem. 289: 312 (2014)). Therefore, Smlt1473’s
structure appears to strongly depend on pH and is used to control its activity
toward different sugars.
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In silico drug discovery has long held the promise to revolutionize the way
drugs are designed, but has largely failed to deliver. Historically inhibitors
were designed based mainly on static structures that emphasized interaction
energetics but ignored potential contributions from conformational entropy.
This issue has been difficult to address experimentally. Recently, we have
developed an NMR-based approach that employs measures of motion as a
proxy for the conformational entropy. Using an empirical calibration, we
have shown that the resulting ‘‘entropy meter’’ is both robust and general.
We hypothesize that conformational entropy represents a critical ‘‘missing
piece’’ in rational drug design. Using the ‘‘entropy meter,’’ we examine the
effect of conformational entropy on protein-inhibitor interactions using the
drug target and mitogen-activated protein kinase (MAPK) p38a as a model sys-
tem. Given the relatively large size of this protein, all studies were performed in
a perdeuterated background. Using standard methods, we have obtained nearly
complete ILV methyl assignments of this protein. 15N and 13C NMR spin
relaxation experiments were used to determine the sub-ns dynamics of the
protein both in the apo state and bound to either a competitive and a non-
competitive (allosteric) inhibitor. In both cases, we observe the a large unfavor-
able entropic effect of binding. We find that the conformational entropy change
upon binding represents a significant contribution to the overall binding free en-
ergy. These results promote further studies to understand how classes of inhib-
itors may modulate the dynamics and corresponding internal entropy of protein
targets, and how this information can be used to design better lead compounds.
This work was supported by NIH Grant GM100910
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The Alanine-Serine-Cysteine transporter ASCT2 (SLC1A5) is a membrane pro-
tein thatmoves neutral amino acids into cells in exchange for outwardmovementof intracellular amino acid. ASCT2 is highly expressed in peripheral tissues such
as the lung, kidney, intestines, and testis where it contributes to the homeostasis
of intracellular concentrations of neutral amino acids. ASCT2 also plays an
important role in the development of a variety of cancers such as melanoma,
by transporting amino acid nutrients such as glutamine into the proliferating tu-
mors. Therefore,ASCT2 is a key drug targetwith potentially great pharmacolog-
ical importance. Here, we identify seven ASCT2 ligands by computational
modeling and experimental testing. In particular,we construct homologymodels
based on crystallographic structures of the aspartate transporter GltPh in two
different conformations, and optimize the models’ binding sites for protein-
ligand complementarity. Virtual screening of 594,166 compounds including
drugs, metabolites, and fragment-like molecules from the ZINC database, fol-
lowed by experimental testing of 11 top hits with functionalmeasurements using
electrophysiologicalmethods reveals seven ligands including five activators and
two inhibitors. For example, aminooxetane-3-carboxylate is a more efficient
activator than any other known ASCT2 natural or unnatural substrate. Further-
more, two of the hits inhibited ASCT2 mediated glutamine uptake and prolifer-
ation of a melanoma cancer cell line. Our results improve our understanding on
how substrate specificity is determined in amino acid transporters as well as
provide novel scaffolds for developing drugs targeting ASCT2, an emerging
therapeutic target for cancer and neurological disorders.
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Macromolecular delivery by hyperthermia and thermal targeting of SynB1-Cys
ELP-bound Doxorubicin (Dox) to solid tumors is investigated in animal studies
as a means of circumventing multidrug resistance in cancer cells. The structural
changes and hydrodynamic properties of ELP below and above its Transition
Temperature TT make this construct a useful carrier for the delivery of Dox.
At low temperature, the ELPs are soluble and consist of both random coils
and b-turn structures. With increasing temperature ELPs undergo weak associ-
ation, forming repeating type II b-turns and b-spirals. Above the TT, they un-
dergo a cooperative phase transition involving mm size aggregates stabilized by
desolvation. Sedimentation velocity (SV) experiments have shown that ELP is
a nonideal monomer at low temperature, but with increase in temperature un-
dergoes weak isodesmic self-association. Adding Cell Penetrating Peptides
(SynB1) at the N-terminal domain of the ELP decreases its solubility and sta-
bilizes the aggregated state. This study asks how the addition of Dox to SynB1-
Cys ELP affects its biophysical and hydrodynamic behavior at physiological
conditions, and how these changes influence its potential for aggregation and
drug delivery. The preliminary SV results presented here show an increase in
self-association of SynB1-Cys ELP-Dox at 20C relative to the unlabeled
construct. The goal of these experiments is to investigate the impact of different
labeling efficiencies (10-90%) on self-association and TT. Preliminary
turbidity results on unlabeled SynB1-Cys ELP in PBS show that TT decreases
linearly with increase in the logarithm of the ELP concentration as solutions are
heated from 20 to 60C. The process is reversible as solutions are cooled to
20C. The degree of conformational change associated with the TT will also
be monitored using CD and FT-IR experiments.
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Fibroblast growth factors (FGFs) lack signal sequences, and are exported
through endoplasmic reticulum (ER)-Golgi-independent non-classical routes.
FGFs work as modulators of various cellular activities like mitosis, differenti-
ation, survival etc. Among the FGF family, which comprises of 23 different
heparin proteins, human FGF-1 (hFGF-1), a potent angiogenic factors are
one of the targets in cancer inhibition, as they are involved in blood vessel for-
mation in tissues. There has been intensive research directed at the develop-
ment of drugs that could effectively inhibit angiogenesis. In this context, the
purpose of this study is to fully understand the molecular principles essential
to determine probability of inhibition of hFGF-1 signaling transduction by im-
atinib. Imatinib, a 2-phenyl amino pyrimidine derivative is a tyrosine kinase in-
hibitor with antineoplastic activity. Imatinib binds to the intracellular pocket
located within tyrosine kinases and inhibit the downstream cell proliferation
events, but the exact molecular mechanism is still elusive. In this study, expres-
sion of hFGF-1 in recombinant E.coliwas carried out, and the expressed protein
was purified using heparin affinity column chromatography. The structural in-
teractions governing imatinib-hFGF-1 interaction was studied by monitoring its
